The mycotoxin aflatoxin B1 stimulates Epstein–Barr virus-induced B-cell transformation in in vitro and in vivo experimental models

R. Accardi, H. Gruffat, C. Sirand, F. Fusil, T. Gheit, H. Hernandez-Vargas, F. Le Calvez-Kelm, A. Traverse-Glehen, F.-L. Cosset, E. Manet, C. P. Wild and M. Tommasino

Although Epstein–Barr virus (EBV) infection is widely distributed, certain EBV-driven malignancies are geographically restricted. EBV-associated Burkitt’s lymphoma (eBL) is endemic in children living in sub-Saharan Africa. This population is heavily exposed to food contaminated with the mycotoxin aflatoxin B1 (AFB1). Here, we show that exposure to AFB1 in in vitro and in vivo models induces activation of the EBV lytic cycle and increases EBV load, two events that are associated with an increased risk of eBL in vivo. AFB1 treatment leads to the alteration of cellular gene expression, with consequent activations of signalling pathways, e.g. PI3K, that in turn mediate reactivation of the EBV life cycle. Finally, we show that AFB1 triggers EBV-driven cellular transformation both in primary human B cells and in a humanized animal model. In summary, our data provide evidence for a role of AFB1 as a co-factor in EBV-mediated carcinogenesis

Article alert

Share this article

September, 2015


Products used in this publication

  • ChIP kit icon
    iDeal ChIP-seq kit for Histones
  • ChIP kit icon
    iDeal ChIP-seq kit for Transcription Factors


  • Virtual ChIL-seq webinar
    Dec 8, 2021
 See all events


 See all news

The European Regional Development Fund and Wallonia are investing in your future.

Extension of industrial buildings and new laboratories.


       Site map   |   Contact us   |   Conditions of sales   |   Conditions of purchase   |   Privacy policy   |   Diagenode Diagnostics